ESSA Pharma Inc. Updates Nasdaq Due Bill Trading for Cash Distribution Clarification

ESSA Pharma Inc. Update on Nasdaq Due Bill Trading

On August 14, 2025, ESSA Pharma Inc. (NASDAQ: EPIX) informed the public about a cash distribution of $80 million as part of their strategic transition. This distribution is designated for shareholders, acknowledging the winding-up of their business in collaboration with XenoTherapeutics, a non-profit biotechnology organization. This planned transaction marks a significant movement in ESSA's operational framework.

The Nasdaq Stock Market set the ex-dividend date for the distribution on August 25, 2025, which is the first business day following the payment date. Payment to the shareholders was executed on August 22, 2025, allowing each shareholder to receive approximately $1.6910318 per common share, minus applicable withholding taxes. This is significant as it represents a robust return on investment for shareholders amidst the company's restructuring efforts.

However, there was a minor error regarding the due bills related to the common shares. Initially, the company issued a statement indicating that common shares would trade with due bills from August 19 to August 25, 2025. The correct due bill period, however, should have been from August 19 to August 22, 2025. Therefore, shares traded without due bills on August 25, transitioning to an “ex-dividend” basis on that date.

Understanding the Background of this Transaction

ESSA Pharma Inc. has centered its research on developing novel therapies aimed at treating prostate cancer. The decision to distribute capital back to its shareholders reflects a strategic pivot, potentially influenced by recent dynamics and arrangements with XenoTherapeutics. This acquisition aims to facilitate a smoother transition for existing shareholders and uphold investor confidence, despite the cessation of current business activities.

The implications of such moves are multi-faceted. From an investor's perspective, it suggests that while the company is winding down its current business model, there remains a proactive effort to deliver value to those who have supported the firm. This points toward a responsible and strategic approach in managing shareholder interests during a time of transformation.

Future Considerations and Forward-Looking Statements

It is important to note that the company's official communications include forward-looking statements concerning future operations and financial performance. These outlooks are inherently fraught with uncertainties and risks which may significantly impact actual outcomes. Factors influencing these projections include completion timeframes for the transaction, regulatory approvals, and the market’s reaction to the corporate restructuring. As ESSA navigates this critical period, stakeholders are encouraged to remain vigilant regarding ongoing developments.

In closing, while change can induce uncertainty, ESSA Pharma’s clear prioritization of shareholder interests speaks volumes about its commitment to maintaining a strong relationship with its investors. The company remains committed to transparency as it transitions and restructures its operations, illustrating an understanding of both market dynamics and the responsible stewardship of investor capital.

For more information about ESSA Pharma Inc. and its ongoing developments, you can visit www.essapharma.com.